Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UCB's Keppra Follow-On Briviact Gains FDA Nod For Epileptic Seizures

This article was originally published in The Pink Sheet Daily

Executive Summary

A next-generation version of levetiracetam, brivaracetam could help UCB recapture some revenue it's losing to generic competition for the mature epilepsy drug.

Advertisement

Related Content

UCB Predicts Briviact Sales Of €450m by 2026; Plans New Partnerships
UCB Exercises Tozadenant Option But Asks Biotie To Move It To Phase III
Epilepsy NMEs: A View Of The Playing Field

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register